CN102498110A - 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 - Google Patents

作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 Download PDF

Info

Publication number
CN102498110A
CN102498110A CN2010800358308A CN201080035830A CN102498110A CN 102498110 A CN102498110 A CN 102498110A CN 2010800358308 A CN2010800358308 A CN 2010800358308A CN 201080035830 A CN201080035830 A CN 201080035830A CN 102498110 A CN102498110 A CN 102498110A
Authority
CN
China
Prior art keywords
amino
bases
pyrazoles
pyrimidine
formamides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800358308A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·柯丁
M·R·麦克利德斯
H·R·海曼
R·R·弗里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of CN102498110A publication Critical patent/CN102498110A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800358308A 2009-06-10 2010-06-08 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 Pending CN102498110A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18575809P 2009-06-10 2009-06-10
US61/185758 2009-06-10
PCT/US2010/037801 WO2010144468A1 (en) 2009-06-10 2010-06-08 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102498110A true CN102498110A (zh) 2012-06-13

Family

ID=42333314

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800358308A Pending CN102498110A (zh) 2009-06-10 2010-06-08 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶

Country Status (7)

Country Link
US (1) US8426408B2 (https=)
EP (1) EP2440548A1 (https=)
JP (1) JP2012529522A (https=)
CN (1) CN102498110A (https=)
CA (1) CA2764983A1 (https=)
MX (1) MX2011013325A (https=)
WO (1) WO2010144468A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104926824A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN106588885A (zh) * 2016-11-10 2017-04-26 浙江大学 2‑取代芳环‑嘧啶类衍生物及制备和应用
WO2021078021A1 (zh) * 2019-10-24 2021-04-29 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN118440052A (zh) * 2024-07-05 2024-08-06 四川大学 一种化合物及其在制备tyk2激酶抑制剂中的用途
WO2024179393A1 (zh) * 2023-02-27 2024-09-06 科辉智药(深圳)新药研究中心有限公司 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
HRP20172006T1 (hr) * 2010-11-10 2018-02-09 Genentech, Inc. Derivati pirazol-aminopiridina kao lrrk2-modulatori
SMT202400031T1 (it) 2011-04-22 2024-03-13 Signal Pharm Llc Diamminocarbossammide e diamminocarbonitrile pirimidine sostituite, loro composizioni e metodi di trattamento con esse
RU2637947C2 (ru) * 2012-05-03 2017-12-08 Дженентек, Инк. Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
ES2792979T3 (es) 2013-08-22 2020-11-12 Jubilant Biosys Ltd Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
MX2016012574A (es) * 2014-03-28 2017-09-26 Calitor Sciences Llc Compuestos heteroarilo sustituidos y metodos de uso.
EP3206691B1 (en) * 2014-10-14 2018-09-19 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
BR112017012795A2 (pt) 2014-12-16 2018-01-02 Signal Pharmaceuticals, Llc Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida
EP3233808B1 (en) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA3208587A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2017048675A1 (en) * 2015-09-17 2017-03-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374301A (en) * 1990-07-26 1994-12-20 Zeneca Limited Inks suitable for use in ink jet printing
GB9303912D0 (en) 1993-02-26 1993-04-14 Zeneca Ltd Inks
JP3880076B2 (ja) 1994-02-25 2007-02-14 キヤノン株式会社 インク、インクジェット記録方法、記録ユニット、インクカートリッジ及びインクジェット記録装置
JPH08113744A (ja) 1994-08-25 1996-05-07 Canon Inc インク、これを用いたインクジェット記録方法及びかかるインクを備えた記録機器
US6117996A (en) * 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
JP3106966B2 (ja) * 1996-07-17 2000-11-06 富士ゼロックス株式会社 インクジェット記録用インク及びインクジェット記録方法
JPH1060338A (ja) * 1996-08-21 1998-03-03 Fuji Xerox Co Ltd インクジェット記録用インク及びインクジェット記録方法
US5980623A (en) * 1997-01-29 1999-11-09 Fuji Xerox Co., Ltd. Ink set for ink jet recording and ink jet recording method
JP3829419B2 (ja) 1997-07-09 2006-10-04 三菱化学株式会社 カラー画像の形成方法
WO2000038683A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
US7141581B2 (en) * 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
NZ585188A (en) * 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP1763514A2 (en) 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7812166B2 (en) * 2004-10-29 2010-10-12 Abbott Laboratories Kinase inhibitors
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
JP2008520713A (ja) * 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
EP1903045A1 (en) 2005-05-27 2008-03-26 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine derivative
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006131768A2 (en) 2005-06-10 2006-12-14 Prometic Biosciences Limited Triazines as protein binding ligands
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147831A1 (en) * 2007-05-23 2008-12-04 Smithkline Beecham Corporation Anthranilamides

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104926824A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926794A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926795A (zh) * 2014-03-17 2015-09-23 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926824B (zh) * 2014-03-17 2017-07-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN104926794B (zh) * 2014-03-17 2017-12-05 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN106588885A (zh) * 2016-11-10 2017-04-26 浙江大学 2‑取代芳环‑嘧啶类衍生物及制备和应用
WO2018086547A1 (zh) * 2016-11-10 2018-05-17 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
WO2021078021A1 (zh) * 2019-10-24 2021-04-29 嘉兴特科罗生物科技有限公司 一种小分子化合物
WO2024179393A1 (zh) * 2023-02-27 2024-09-06 科辉智药(深圳)新药研究中心有限公司 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用
CN118440052A (zh) * 2024-07-05 2024-08-06 四川大学 一种化合物及其在制备tyk2激酶抑制剂中的用途

Also Published As

Publication number Publication date
CA2764983A1 (en) 2010-12-16
JP2012529522A (ja) 2012-11-22
EP2440548A1 (en) 2012-04-18
MX2011013325A (es) 2012-04-30
US8426408B2 (en) 2013-04-23
US20100317680A1 (en) 2010-12-16
WO2010144468A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
CN102498110A (zh) 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶
US8293738B2 (en) Indazole inhibitors of kinase
TWI500621B (zh) 具改良ｃｙｐ安全性之激酶抑制劑
US9718821B2 (en) Pyridopyrimidinone inhibitors of kinases
MX2012013196A (es) Inhibidores de pirrolopiridina y pirrolopirimidina de cinasas.
KR20110102473A (ko) 헤테로시클릭 화합물 및 사용 방법
US20140155389A1 (en) Bicyclic inhibitors of alk
CN102459236B (zh) 激酶活性的嘧啶抑制剂
JP2014530867A (ja) キナーゼのピリドピリミジノン阻害剤
US8859546B2 (en) Picolinamide inhibitors of kinases
US9212192B2 (en) Bicyclic carboxamide inhibitors of kinases
CN109422749A (zh) 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
CN103415516A (zh) Alk的双环抑制剂
US8436179B2 (en) Kinase inhibitor with improved solubility profile
CN103443102A (zh) 激酶的双环甲酰胺抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130618

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130618

Address after: Illinois State

Applicant after: ABBVIE company

Address before: Illinois State

Applicant before: Abbott GmbH. & Co. Kg

AD01 Patent right deemed abandoned

Effective date of abandoning: 20120613

C20 Patent right or utility model deemed to be abandoned or is abandoned